SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Childs who wrote (207)1/9/1998 6:21:00 PM
From: Todd D. Wiener  Read Replies (1) of 783
 
Biotechs See Strong Sales Boosting 4Q Earnings

Dow Jones Newswires

BioChem Pharma Inc. (BCHE) saw a dramatic rebound in sales of its AIDS drug 3TC, or Epivir,
in the quarter, according to Silverman. He predicts sales rose 20% in the fourth quarter compared
with the third quarter. The expected rise was helped in part by Glaxo Wellcome PLC's (GLX)
launching of its Combivir drug, a combination of BioChem's 3TC and Glaxo's Retrovir, at the end
of September. Analysts expect BioChem, of Laval, Quebec, to have earned 16 cents a share in the
latest period, up from 14 cents a share a year ago, according to First Call.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News